Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events. The 23 rd Annual NewsMakers in the Biotech Industry - New York, September 9, 2016 September 9, 10:00 a.m. EDT - Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation 7th Non-Coding RNA & RNAi Therapeutics Conference - Boston, September 14-15, 2016 September 14, 4:30 p.m. EDT - Erik Bush, Ph.D., Arrowhead director of extrahepatic targeting will deliver an oral presentation titled, "Targeted delivery strategies using Dynamic Polyconjugate TM (DPC TM ) technology" 2016 International HBV Meeting - Seoul, Korea, September 21-24, 2016 September 24, 8:30 a.m. KST - Zhao Xu, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, "Functional HBsAg-encoding HBV fusion transcripts are produced from integrated HBV DNA in chronically infected chimpanzees - evidence from single molecule, real time (SMRT) sequencing" Copies of presentation materials and webcasts can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. The company's pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.